The North America stem cell assay market size was valued at USD 7.82 Billion in 2025, driven by the increased investment in stem cell research in the region. The market is expected to grow at a CAGR of 10.08% during the forecast period of 2026-2035, with the values likely to rise from USD 20.43 Billion by 2035.
Base Year
Historical Period
Forecast Period
In May 2023 , a study published in Cell Reports Medicine revealed that a cancer stem cell assay called ChemoID can accurately predict clinical outcomes in response to chemotherapy, improving the survival of patients with recurrent glioblastoma.
In April 2023, Discovery Life Sciences acquired ReachBio Research Labs to expand its offerings in drug discovery and preclinical development by leveraging ReachBio’s expertise in primary cell biology, particularly blood and bone marrow stem cell assays.
According to the American Cancer Society, it is estimated that 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States in 2024.
Compound Annual Growth Rate
10.08%
Value in USD Billion
2026-2035
*this image is indicative*
Stem cell assay is a laboratory technique that helps to evaluate the behavior and function of stem cells. These assays find their applications in studying stem cell biology and assessing their potential therapeutic use. The rising cases of various chronic diseases in the region such as cancer are expected to directly impact the demand for novel treatment options, thereby driving the North America stem cell assay market growth. For instance, according to the American Cancer Society, it is estimated that 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States in 2024. Further, increased applications of stem cell assays in drug discovery and regenerative medicine are likely to augment the market size in the forecast period.
In North America, the rising impetus for stem cell research is resulting in advancements in stem cell assay methods and therapies. The development of innovative methods is expected to boost North America stem cell assay market demand as they can assist healthcare professionals in personalizing chemotherapy selection for cancer patients and in identifying the most effective therapy for each patient. In May 2023 , a study published in Cell Reports Medicine revealed that a cancer stem cell assay called ChemoID can accurately predict clinical outcomes in response to chemotherapy, improving the survival of patients with recurrent glioblastoma. In the randomized trial, the group guided by the ChemoID assay showed a median survival of 12.5 months, compared to 9 months in the physician-choice group. These findings offer a promising approach to providing more affordable treatment for patients with recurrent glioblastoma in lower socioeconomic groups in the United States.
North America stem cell assay market share is likely to be impacted by increased merger and acquisition initiatives among the key market players. In April 2023, a United States-based company specializing in biospecimen, biomarker, and proteogenomics Discovery Life Sciences acquired ReachBio Research Labs, a life sciences company based in Seattle known for their cell-based assays, drug screening services, and predictive hematotoxicity. The acquisition will enable Discovery Life Science to expand its offerings in drug discovery and preclinical development by leveraging ReachBio’s expertise in primary cell biology, particularly blood and bone marrow stem cell assays. The growing number of such strategic partnerships is anticipated to accelerate market growth in the coming years.
Other factors that fuel the market growth are the advancements in stem cell technologies resulting in enhanced efficiency and throughput of stem cell assays, increased healthcare expenditure, and rising funding for stem cell-based research. Further, the growing demand for personalized medicine and precision therapies will accelerate the market growth in the region.
North America Stem Cell Assay Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Breakup by Product & Service
Breakup by Cell Type
Breakup by Type
Breakup by Treatment
Breakup by Application
Breakup by End User
Breakup by Region
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$4299 $3869
$2699 $2429
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 7.82 Billion in 2025 driven by the increased investment in stem cell research in the region.
The market is anticipated to grow at a CAGR of 10.08% during the forecast period of 2026-2035, likely to reach a market value of USD 20.43 Billion by 2035.
The growing prevalence of chronic diseases and the rising healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is the increased merger and acquisition initiatives among the key market players. In April 2023, Discovery Life Sciences acquired ReachBio Research Labs, a life sciences company based in Seattle known for its cell-based assays, drug screening services, and predictive hematotoxicity.
Based on the product and services, the market is segmented into flow cytometers, cell imaging and analysis systems, microelectrode arrays, automated cell counters, and kits.
Treatments available in the market include allogeneic stem cell therapy, autologous stem cell therapy, and syngeneic stem cell therapy.
By type, the market is divided into viability/cytotoxicity assays, isolation and purification assays, cell identification assays, proliferation assays, differentiation assays, function assays, and apoptosis assays, among others.
The market breakup by cell type includes adult stem cells, human embryonic stem cells, and pluripotent.
End users of the market are biopharmaceutical and biotechnology companies, as well as academic and research institutes, among others.
Major applications areas of stem cell assays include regenerative medicine and therapy development, drug discovery and development, along with clinical research, among others.
The market segmentation by countries includes the United States of America and Canada.
The key market players include Thermo Fisher Scientific, PerkinElmer, Stemcell Technologies, Merck, Bio-Rad Laboratories, Agilent Technologies, Promega, Bio-Techne, and Cell Biolabs.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product & Service |
|
| Breakup by Cell Type |
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share